Global Betahistine Market

Betahistine Comprehensive Study by Type (8mg, 16mg, 24mg), Application (Vertigo, Tinnitus, Nausea), Sales Channel (Online, Offline) Players and Region - Global Market Outlook to 2026

Betahistine Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Betahistine Market?

Betahistine is a medicine that is used to treat the symptoms of Ménière's disease. Betahistine can be taken by adults aged 18 years and over and is not prescribed for children. Ménière's disease is a condition of the inner ear. It is normally causes attacks of dizziness with a spinning sensation which is vertigo, hearing loss and noises in the ear (tinnitus). The attacks can vary in severity, and in how often they occur. It is thought that a build-up of fluid in the inner ear causes the symptoms. The medicine holds 50 mg lactose monohydrate for 8 mg strength and 100 mg lactose monohydrate for 16 mg strength. Patients with rare hereditary irregularities of galactose tolerance, individuals with Lapp lactase deficiency or glucose-galactose malabsorption should not use this medication. The oral betahistine is approved for the treatment of Ménière’s disease and vestibular vertigo in more than 80 countries globally. However, In United States betahistine has not been approved for marketing for the past few decades.

Highlights from Betahistine Market Study
AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledAuris Medical Holding AG (Switzerland), TOWA PHARMACEUTICAL CO., LTD (Japan), Ciclum Farma Unipessoal (Portugal), EA Pharma Co., Ltd. (Japan), Nichi-Iko Pharmaceutical (Japan), DOC Generici (Italy), Takeda Pharmaceutical Company Limited (Japan), Orion Corporation (Finland), HENNIG ARZNEIMITTEL GmbH & Co. KG (Germany), Disphar International B.V. (Netherlands) and Mylan (United States)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that Asian Players will contribute to the maximum growth of Global Betahistine market throughout the forecasted period.

Auris Medical Holding AG (Switzerland), TOWA PHARMACEUTICAL CO., LTD (Japan), Ciclum Farma Unipessoal (Portugal), EA Pharma Co., Ltd. (Japan), Nichi-Iko Pharmaceutical (Japan), DOC Generici (Italy), Takeda Pharmaceutical Company Limited (Japan), Orion Corporation (Finland), HENNIG ARZNEIMITTEL GmbH & Co. KG (Germany), Disphar International B.V. (Netherlands) and Mylan (United States) are some of the key players profiled in the study.

Betahistine Market Segmentation:
ScopeSub-Segments
Application / End UserVertigo, Tinnitus and Nausea
Type8mg, 16mg and 24mg
Sales ChannelOnline,Offline


On the basis of geography, the market of Betahistine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
High Prevalence of Meniere’s Disease and Increasing Awareness of This Disorder Is another Important Factor for the Market Growth

Market Growth Drivers:
Rise in Geriatric Population, Environmental Pollution, Noise Pollution and Increase in the Changing In Lifestyle

Challenges:
Low Healthcare Expenditure in Developing Regions Also Acts As a Market Challenge and Can Cause Unwanted Side-Effects Although Not Everyone Experiences Them

Restraints:
Lack of Any Approved Drug or Treatment Option Is Restricting the Market Growth

Opportunities:
Rising Investment in the Research & Development for the Treatments for Meniere’s Disease and Government Initiative to Increase Awareness Is Elevating the Market Growth

Key Target Audience
Manufacturers of Betahistine, Suppliers of Betahistine, Wholesalers, Distributors and Retailers of Betahistine, Pharmaceutical Industry, Regulatory Bodies and Governmental bodies




Report Objectives / Segmentation Covered

By Type
  • 8mg
  • 16mg
  • 24mg
By Application
  • Vertigo
  • Tinnitus
  • Nausea
By Sales Channel
  • Online
  • Offline

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in Geriatric Population, Environmental Pollution, Noise Pollution
      • 3.2.2. Increase in the Changing In Lifestyle
    • 3.3. Market Challenges
      • 3.3.1. Low Healthcare Expenditure in Developing Regions Also Acts As a Market Challenge
      • 3.3.2. Can Cause Unwanted Side-Effects Although Not Everyone Experiences Them
    • 3.4. Market Trends
      • 3.4.1. High Prevalence of Meniere’s Disease
      • 3.4.2. Increasing Awareness of This Disorder Is another Important Factor for the Market Growth
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Betahistine, by Type, Application, Sales Channel and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Betahistine (Value)
      • 5.2.1. Global Betahistine by: Type (Value)
        • 5.2.1.1. 8mg
        • 5.2.1.2. 16mg
        • 5.2.1.3. 24mg
      • 5.2.2. Global Betahistine by: Application (Value)
        • 5.2.2.1. Vertigo
        • 5.2.2.2. Tinnitus
        • 5.2.2.3. Nausea
      • 5.2.3. Global Betahistine by: Sales Channel (Value)
        • 5.2.3.1. Online
        • 5.2.3.2. Offline
      • 5.2.4. Global Betahistine Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Betahistine (Volume)
      • 5.3.1. Global Betahistine by: Type (Volume)
        • 5.3.1.1. 8mg
        • 5.3.1.2. 16mg
        • 5.3.1.3. 24mg
      • 5.3.2. Global Betahistine by: Application (Volume)
        • 5.3.2.1. Vertigo
        • 5.3.2.2. Tinnitus
        • 5.3.2.3. Nausea
      • 5.3.3. Global Betahistine by: Sales Channel (Volume)
        • 5.3.3.1. Online
        • 5.3.3.2. Offline
      • 5.3.4. Global Betahistine Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Betahistine (Price)
      • 5.4.1. Global Betahistine by: Type (Price)
  • 6. Betahistine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Auris Medical Holding AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. TOWA PHARMACEUTICAL CO., LTD (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Ciclum Farma Unipessoal (Portugal)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. EA Pharma Co., Ltd. (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Nichi-Iko Pharmaceutical (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. DOC Generici (Italy)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Orion Corporation (Finland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. HENNIG ARZNEIMITTEL GmbH & Co. KG (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Disphar International B.V. (Netherlands)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Mylan (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Betahistine Sale, by Type, Application, Sales Channel and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Betahistine (Value)
      • 7.2.1. Global Betahistine by: Type (Value)
        • 7.2.1.1. 8mg
        • 7.2.1.2. 16mg
        • 7.2.1.3. 24mg
      • 7.2.2. Global Betahistine by: Application (Value)
        • 7.2.2.1. Vertigo
        • 7.2.2.2. Tinnitus
        • 7.2.2.3. Nausea
      • 7.2.3. Global Betahistine by: Sales Channel (Value)
        • 7.2.3.1. Online
        • 7.2.3.2. Offline
      • 7.2.4. Global Betahistine Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Betahistine (Volume)
      • 7.3.1. Global Betahistine by: Type (Volume)
        • 7.3.1.1. 8mg
        • 7.3.1.2. 16mg
        • 7.3.1.3. 24mg
      • 7.3.2. Global Betahistine by: Application (Volume)
        • 7.3.2.1. Vertigo
        • 7.3.2.2. Tinnitus
        • 7.3.2.3. Nausea
      • 7.3.3. Global Betahistine by: Sales Channel (Volume)
        • 7.3.3.1. Online
        • 7.3.3.2. Offline
      • 7.3.4. Global Betahistine Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Betahistine (Price)
      • 7.4.1. Global Betahistine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Betahistine: by Type(USD Million)
  • Table 2. Betahistine 8mg , by Region USD Million (2016-2021)
  • Table 3. Betahistine 16mg , by Region USD Million (2016-2021)
  • Table 4. Betahistine 24mg , by Region USD Million (2016-2021)
  • Table 5. Betahistine: by Application(USD Million)
  • Table 6. Betahistine Vertigo , by Region USD Million (2016-2021)
  • Table 7. Betahistine Tinnitus , by Region USD Million (2016-2021)
  • Table 8. Betahistine Nausea , by Region USD Million (2016-2021)
  • Table 9. Betahistine: by Sales Channel(USD Million)
  • Table 10. Betahistine Online , by Region USD Million (2016-2021)
  • Table 11. Betahistine Offline , by Region USD Million (2016-2021)
  • Table 12. South America Betahistine, by Country USD Million (2016-2021)
  • Table 13. South America Betahistine, by Type USD Million (2016-2021)
  • Table 14. South America Betahistine, by Application USD Million (2016-2021)
  • Table 15. South America Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 16. Brazil Betahistine, by Type USD Million (2016-2021)
  • Table 17. Brazil Betahistine, by Application USD Million (2016-2021)
  • Table 18. Brazil Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 19. Argentina Betahistine, by Type USD Million (2016-2021)
  • Table 20. Argentina Betahistine, by Application USD Million (2016-2021)
  • Table 21. Argentina Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 22. Rest of South America Betahistine, by Type USD Million (2016-2021)
  • Table 23. Rest of South America Betahistine, by Application USD Million (2016-2021)
  • Table 24. Rest of South America Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 25. Asia Pacific Betahistine, by Country USD Million (2016-2021)
  • Table 26. Asia Pacific Betahistine, by Type USD Million (2016-2021)
  • Table 27. Asia Pacific Betahistine, by Application USD Million (2016-2021)
  • Table 28. Asia Pacific Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 29. China Betahistine, by Type USD Million (2016-2021)
  • Table 30. China Betahistine, by Application USD Million (2016-2021)
  • Table 31. China Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 32. Japan Betahistine, by Type USD Million (2016-2021)
  • Table 33. Japan Betahistine, by Application USD Million (2016-2021)
  • Table 34. Japan Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 35. India Betahistine, by Type USD Million (2016-2021)
  • Table 36. India Betahistine, by Application USD Million (2016-2021)
  • Table 37. India Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 38. South Korea Betahistine, by Type USD Million (2016-2021)
  • Table 39. South Korea Betahistine, by Application USD Million (2016-2021)
  • Table 40. South Korea Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 41. Taiwan Betahistine, by Type USD Million (2016-2021)
  • Table 42. Taiwan Betahistine, by Application USD Million (2016-2021)
  • Table 43. Taiwan Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 44. Australia Betahistine, by Type USD Million (2016-2021)
  • Table 45. Australia Betahistine, by Application USD Million (2016-2021)
  • Table 46. Australia Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 47. Rest of Asia-Pacific Betahistine, by Type USD Million (2016-2021)
  • Table 48. Rest of Asia-Pacific Betahistine, by Application USD Million (2016-2021)
  • Table 49. Rest of Asia-Pacific Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 50. Europe Betahistine, by Country USD Million (2016-2021)
  • Table 51. Europe Betahistine, by Type USD Million (2016-2021)
  • Table 52. Europe Betahistine, by Application USD Million (2016-2021)
  • Table 53. Europe Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 54. Germany Betahistine, by Type USD Million (2016-2021)
  • Table 55. Germany Betahistine, by Application USD Million (2016-2021)
  • Table 56. Germany Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 57. France Betahistine, by Type USD Million (2016-2021)
  • Table 58. France Betahistine, by Application USD Million (2016-2021)
  • Table 59. France Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 60. Italy Betahistine, by Type USD Million (2016-2021)
  • Table 61. Italy Betahistine, by Application USD Million (2016-2021)
  • Table 62. Italy Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 63. United Kingdom Betahistine, by Type USD Million (2016-2021)
  • Table 64. United Kingdom Betahistine, by Application USD Million (2016-2021)
  • Table 65. United Kingdom Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 66. Netherlands Betahistine, by Type USD Million (2016-2021)
  • Table 67. Netherlands Betahistine, by Application USD Million (2016-2021)
  • Table 68. Netherlands Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 69. Rest of Europe Betahistine, by Type USD Million (2016-2021)
  • Table 70. Rest of Europe Betahistine, by Application USD Million (2016-2021)
  • Table 71. Rest of Europe Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 72. MEA Betahistine, by Country USD Million (2016-2021)
  • Table 73. MEA Betahistine, by Type USD Million (2016-2021)
  • Table 74. MEA Betahistine, by Application USD Million (2016-2021)
  • Table 75. MEA Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 76. Middle East Betahistine, by Type USD Million (2016-2021)
  • Table 77. Middle East Betahistine, by Application USD Million (2016-2021)
  • Table 78. Middle East Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 79. Africa Betahistine, by Type USD Million (2016-2021)
  • Table 80. Africa Betahistine, by Application USD Million (2016-2021)
  • Table 81. Africa Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 82. North America Betahistine, by Country USD Million (2016-2021)
  • Table 83. North America Betahistine, by Type USD Million (2016-2021)
  • Table 84. North America Betahistine, by Application USD Million (2016-2021)
  • Table 85. North America Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 86. United States Betahistine, by Type USD Million (2016-2021)
  • Table 87. United States Betahistine, by Application USD Million (2016-2021)
  • Table 88. United States Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 89. Canada Betahistine, by Type USD Million (2016-2021)
  • Table 90. Canada Betahistine, by Application USD Million (2016-2021)
  • Table 91. Canada Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 92. Mexico Betahistine, by Type USD Million (2016-2021)
  • Table 93. Mexico Betahistine, by Application USD Million (2016-2021)
  • Table 94. Mexico Betahistine, by Sales Channel USD Million (2016-2021)
  • Table 95. Betahistine Sales: by Type(K Tons)
  • Table 96. Betahistine Sales 8mg , by Region K Tons (2016-2021)
  • Table 97. Betahistine Sales 16mg , by Region K Tons (2016-2021)
  • Table 98. Betahistine Sales 24mg , by Region K Tons (2016-2021)
  • Table 99. Betahistine Sales: by Application(K Tons)
  • Table 100. Betahistine Sales Vertigo , by Region K Tons (2016-2021)
  • Table 101. Betahistine Sales Tinnitus , by Region K Tons (2016-2021)
  • Table 102. Betahistine Sales Nausea , by Region K Tons (2016-2021)
  • Table 103. Betahistine Sales: by Sales Channel(K Tons)
  • Table 104. Betahistine Sales Online , by Region K Tons (2016-2021)
  • Table 105. Betahistine Sales Offline , by Region K Tons (2016-2021)
  • Table 106. South America Betahistine Sales, by Country K Tons (2016-2021)
  • Table 107. South America Betahistine Sales, by Type K Tons (2016-2021)
  • Table 108. South America Betahistine Sales, by Application K Tons (2016-2021)
  • Table 109. South America Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 110. Brazil Betahistine Sales, by Type K Tons (2016-2021)
  • Table 111. Brazil Betahistine Sales, by Application K Tons (2016-2021)
  • Table 112. Brazil Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 113. Argentina Betahistine Sales, by Type K Tons (2016-2021)
  • Table 114. Argentina Betahistine Sales, by Application K Tons (2016-2021)
  • Table 115. Argentina Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 116. Rest of South America Betahistine Sales, by Type K Tons (2016-2021)
  • Table 117. Rest of South America Betahistine Sales, by Application K Tons (2016-2021)
  • Table 118. Rest of South America Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 119. Asia Pacific Betahistine Sales, by Country K Tons (2016-2021)
  • Table 120. Asia Pacific Betahistine Sales, by Type K Tons (2016-2021)
  • Table 121. Asia Pacific Betahistine Sales, by Application K Tons (2016-2021)
  • Table 122. Asia Pacific Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 123. China Betahistine Sales, by Type K Tons (2016-2021)
  • Table 124. China Betahistine Sales, by Application K Tons (2016-2021)
  • Table 125. China Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 126. Japan Betahistine Sales, by Type K Tons (2016-2021)
  • Table 127. Japan Betahistine Sales, by Application K Tons (2016-2021)
  • Table 128. Japan Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 129. India Betahistine Sales, by Type K Tons (2016-2021)
  • Table 130. India Betahistine Sales, by Application K Tons (2016-2021)
  • Table 131. India Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 132. South Korea Betahistine Sales, by Type K Tons (2016-2021)
  • Table 133. South Korea Betahistine Sales, by Application K Tons (2016-2021)
  • Table 134. South Korea Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 135. Taiwan Betahistine Sales, by Type K Tons (2016-2021)
  • Table 136. Taiwan Betahistine Sales, by Application K Tons (2016-2021)
  • Table 137. Taiwan Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 138. Australia Betahistine Sales, by Type K Tons (2016-2021)
  • Table 139. Australia Betahistine Sales, by Application K Tons (2016-2021)
  • Table 140. Australia Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 141. Rest of Asia-Pacific Betahistine Sales, by Type K Tons (2016-2021)
  • Table 142. Rest of Asia-Pacific Betahistine Sales, by Application K Tons (2016-2021)
  • Table 143. Rest of Asia-Pacific Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 144. Europe Betahistine Sales, by Country K Tons (2016-2021)
  • Table 145. Europe Betahistine Sales, by Type K Tons (2016-2021)
  • Table 146. Europe Betahistine Sales, by Application K Tons (2016-2021)
  • Table 147. Europe Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 148. Germany Betahistine Sales, by Type K Tons (2016-2021)
  • Table 149. Germany Betahistine Sales, by Application K Tons (2016-2021)
  • Table 150. Germany Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 151. France Betahistine Sales, by Type K Tons (2016-2021)
  • Table 152. France Betahistine Sales, by Application K Tons (2016-2021)
  • Table 153. France Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 154. Italy Betahistine Sales, by Type K Tons (2016-2021)
  • Table 155. Italy Betahistine Sales, by Application K Tons (2016-2021)
  • Table 156. Italy Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 157. United Kingdom Betahistine Sales, by Type K Tons (2016-2021)
  • Table 158. United Kingdom Betahistine Sales, by Application K Tons (2016-2021)
  • Table 159. United Kingdom Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 160. Netherlands Betahistine Sales, by Type K Tons (2016-2021)
  • Table 161. Netherlands Betahistine Sales, by Application K Tons (2016-2021)
  • Table 162. Netherlands Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 163. Rest of Europe Betahistine Sales, by Type K Tons (2016-2021)
  • Table 164. Rest of Europe Betahistine Sales, by Application K Tons (2016-2021)
  • Table 165. Rest of Europe Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 166. MEA Betahistine Sales, by Country K Tons (2016-2021)
  • Table 167. MEA Betahistine Sales, by Type K Tons (2016-2021)
  • Table 168. MEA Betahistine Sales, by Application K Tons (2016-2021)
  • Table 169. MEA Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 170. Middle East Betahistine Sales, by Type K Tons (2016-2021)
  • Table 171. Middle East Betahistine Sales, by Application K Tons (2016-2021)
  • Table 172. Middle East Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 173. Africa Betahistine Sales, by Type K Tons (2016-2021)
  • Table 174. Africa Betahistine Sales, by Application K Tons (2016-2021)
  • Table 175. Africa Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 176. North America Betahistine Sales, by Country K Tons (2016-2021)
  • Table 177. North America Betahistine Sales, by Type K Tons (2016-2021)
  • Table 178. North America Betahistine Sales, by Application K Tons (2016-2021)
  • Table 179. North America Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 180. United States Betahistine Sales, by Type K Tons (2016-2021)
  • Table 181. United States Betahistine Sales, by Application K Tons (2016-2021)
  • Table 182. United States Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 183. Canada Betahistine Sales, by Type K Tons (2016-2021)
  • Table 184. Canada Betahistine Sales, by Application K Tons (2016-2021)
  • Table 185. Canada Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 186. Mexico Betahistine Sales, by Type K Tons (2016-2021)
  • Table 187. Mexico Betahistine Sales, by Application K Tons (2016-2021)
  • Table 188. Mexico Betahistine Sales, by Sales Channel K Tons (2016-2021)
  • Table 189. Betahistine: by Type(USD/Units)
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Betahistine: by Type(USD Million)
  • Table 202. Betahistine 8mg , by Region USD Million (2022-2027)
  • Table 203. Betahistine 16mg , by Region USD Million (2022-2027)
  • Table 204. Betahistine 24mg , by Region USD Million (2022-2027)
  • Table 205. Betahistine: by Application(USD Million)
  • Table 206. Betahistine Vertigo , by Region USD Million (2022-2027)
  • Table 207. Betahistine Tinnitus , by Region USD Million (2022-2027)
  • Table 208. Betahistine Nausea , by Region USD Million (2022-2027)
  • Table 209. Betahistine: by Sales Channel(USD Million)
  • Table 210. Betahistine Online , by Region USD Million (2022-2027)
  • Table 211. Betahistine Offline , by Region USD Million (2022-2027)
  • Table 212. South America Betahistine, by Country USD Million (2022-2027)
  • Table 213. South America Betahistine, by Type USD Million (2022-2027)
  • Table 214. South America Betahistine, by Application USD Million (2022-2027)
  • Table 215. South America Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 216. Brazil Betahistine, by Type USD Million (2022-2027)
  • Table 217. Brazil Betahistine, by Application USD Million (2022-2027)
  • Table 218. Brazil Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 219. Argentina Betahistine, by Type USD Million (2022-2027)
  • Table 220. Argentina Betahistine, by Application USD Million (2022-2027)
  • Table 221. Argentina Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 222. Rest of South America Betahistine, by Type USD Million (2022-2027)
  • Table 223. Rest of South America Betahistine, by Application USD Million (2022-2027)
  • Table 224. Rest of South America Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 225. Asia Pacific Betahistine, by Country USD Million (2022-2027)
  • Table 226. Asia Pacific Betahistine, by Type USD Million (2022-2027)
  • Table 227. Asia Pacific Betahistine, by Application USD Million (2022-2027)
  • Table 228. Asia Pacific Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 229. China Betahistine, by Type USD Million (2022-2027)
  • Table 230. China Betahistine, by Application USD Million (2022-2027)
  • Table 231. China Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 232. Japan Betahistine, by Type USD Million (2022-2027)
  • Table 233. Japan Betahistine, by Application USD Million (2022-2027)
  • Table 234. Japan Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 235. India Betahistine, by Type USD Million (2022-2027)
  • Table 236. India Betahistine, by Application USD Million (2022-2027)
  • Table 237. India Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 238. South Korea Betahistine, by Type USD Million (2022-2027)
  • Table 239. South Korea Betahistine, by Application USD Million (2022-2027)
  • Table 240. South Korea Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 241. Taiwan Betahistine, by Type USD Million (2022-2027)
  • Table 242. Taiwan Betahistine, by Application USD Million (2022-2027)
  • Table 243. Taiwan Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 244. Australia Betahistine, by Type USD Million (2022-2027)
  • Table 245. Australia Betahistine, by Application USD Million (2022-2027)
  • Table 246. Australia Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 247. Rest of Asia-Pacific Betahistine, by Type USD Million (2022-2027)
  • Table 248. Rest of Asia-Pacific Betahistine, by Application USD Million (2022-2027)
  • Table 249. Rest of Asia-Pacific Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 250. Europe Betahistine, by Country USD Million (2022-2027)
  • Table 251. Europe Betahistine, by Type USD Million (2022-2027)
  • Table 252. Europe Betahistine, by Application USD Million (2022-2027)
  • Table 253. Europe Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 254. Germany Betahistine, by Type USD Million (2022-2027)
  • Table 255. Germany Betahistine, by Application USD Million (2022-2027)
  • Table 256. Germany Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 257. France Betahistine, by Type USD Million (2022-2027)
  • Table 258. France Betahistine, by Application USD Million (2022-2027)
  • Table 259. France Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 260. Italy Betahistine, by Type USD Million (2022-2027)
  • Table 261. Italy Betahistine, by Application USD Million (2022-2027)
  • Table 262. Italy Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 263. United Kingdom Betahistine, by Type USD Million (2022-2027)
  • Table 264. United Kingdom Betahistine, by Application USD Million (2022-2027)
  • Table 265. United Kingdom Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 266. Netherlands Betahistine, by Type USD Million (2022-2027)
  • Table 267. Netherlands Betahistine, by Application USD Million (2022-2027)
  • Table 268. Netherlands Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 269. Rest of Europe Betahistine, by Type USD Million (2022-2027)
  • Table 270. Rest of Europe Betahistine, by Application USD Million (2022-2027)
  • Table 271. Rest of Europe Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 272. MEA Betahistine, by Country USD Million (2022-2027)
  • Table 273. MEA Betahistine, by Type USD Million (2022-2027)
  • Table 274. MEA Betahistine, by Application USD Million (2022-2027)
  • Table 275. MEA Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 276. Middle East Betahistine, by Type USD Million (2022-2027)
  • Table 277. Middle East Betahistine, by Application USD Million (2022-2027)
  • Table 278. Middle East Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 279. Africa Betahistine, by Type USD Million (2022-2027)
  • Table 280. Africa Betahistine, by Application USD Million (2022-2027)
  • Table 281. Africa Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 282. North America Betahistine, by Country USD Million (2022-2027)
  • Table 283. North America Betahistine, by Type USD Million (2022-2027)
  • Table 284. North America Betahistine, by Application USD Million (2022-2027)
  • Table 285. North America Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 286. United States Betahistine, by Type USD Million (2022-2027)
  • Table 287. United States Betahistine, by Application USD Million (2022-2027)
  • Table 288. United States Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 289. Canada Betahistine, by Type USD Million (2022-2027)
  • Table 290. Canada Betahistine, by Application USD Million (2022-2027)
  • Table 291. Canada Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 292. Mexico Betahistine, by Type USD Million (2022-2027)
  • Table 293. Mexico Betahistine, by Application USD Million (2022-2027)
  • Table 294. Mexico Betahistine, by Sales Channel USD Million (2022-2027)
  • Table 295. Betahistine Sales: by Type(K Tons)
  • Table 296. Betahistine Sales 8mg , by Region K Tons (2022-2027)
  • Table 297. Betahistine Sales 16mg , by Region K Tons (2022-2027)
  • Table 298. Betahistine Sales 24mg , by Region K Tons (2022-2027)
  • Table 299. Betahistine Sales: by Application(K Tons)
  • Table 300. Betahistine Sales Vertigo , by Region K Tons (2022-2027)
  • Table 301. Betahistine Sales Tinnitus , by Region K Tons (2022-2027)
  • Table 302. Betahistine Sales Nausea , by Region K Tons (2022-2027)
  • Table 303. Betahistine Sales: by Sales Channel(K Tons)
  • Table 304. Betahistine Sales Online , by Region K Tons (2022-2027)
  • Table 305. Betahistine Sales Offline , by Region K Tons (2022-2027)
  • Table 306. South America Betahistine Sales, by Country K Tons (2022-2027)
  • Table 307. South America Betahistine Sales, by Type K Tons (2022-2027)
  • Table 308. South America Betahistine Sales, by Application K Tons (2022-2027)
  • Table 309. South America Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 310. Brazil Betahistine Sales, by Type K Tons (2022-2027)
  • Table 311. Brazil Betahistine Sales, by Application K Tons (2022-2027)
  • Table 312. Brazil Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 313. Argentina Betahistine Sales, by Type K Tons (2022-2027)
  • Table 314. Argentina Betahistine Sales, by Application K Tons (2022-2027)
  • Table 315. Argentina Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 316. Rest of South America Betahistine Sales, by Type K Tons (2022-2027)
  • Table 317. Rest of South America Betahistine Sales, by Application K Tons (2022-2027)
  • Table 318. Rest of South America Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 319. Asia Pacific Betahistine Sales, by Country K Tons (2022-2027)
  • Table 320. Asia Pacific Betahistine Sales, by Type K Tons (2022-2027)
  • Table 321. Asia Pacific Betahistine Sales, by Application K Tons (2022-2027)
  • Table 322. Asia Pacific Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 323. China Betahistine Sales, by Type K Tons (2022-2027)
  • Table 324. China Betahistine Sales, by Application K Tons (2022-2027)
  • Table 325. China Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 326. Japan Betahistine Sales, by Type K Tons (2022-2027)
  • Table 327. Japan Betahistine Sales, by Application K Tons (2022-2027)
  • Table 328. Japan Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 329. India Betahistine Sales, by Type K Tons (2022-2027)
  • Table 330. India Betahistine Sales, by Application K Tons (2022-2027)
  • Table 331. India Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 332. South Korea Betahistine Sales, by Type K Tons (2022-2027)
  • Table 333. South Korea Betahistine Sales, by Application K Tons (2022-2027)
  • Table 334. South Korea Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 335. Taiwan Betahistine Sales, by Type K Tons (2022-2027)
  • Table 336. Taiwan Betahistine Sales, by Application K Tons (2022-2027)
  • Table 337. Taiwan Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 338. Australia Betahistine Sales, by Type K Tons (2022-2027)
  • Table 339. Australia Betahistine Sales, by Application K Tons (2022-2027)
  • Table 340. Australia Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 341. Rest of Asia-Pacific Betahistine Sales, by Type K Tons (2022-2027)
  • Table 342. Rest of Asia-Pacific Betahistine Sales, by Application K Tons (2022-2027)
  • Table 343. Rest of Asia-Pacific Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 344. Europe Betahistine Sales, by Country K Tons (2022-2027)
  • Table 345. Europe Betahistine Sales, by Type K Tons (2022-2027)
  • Table 346. Europe Betahistine Sales, by Application K Tons (2022-2027)
  • Table 347. Europe Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 348. Germany Betahistine Sales, by Type K Tons (2022-2027)
  • Table 349. Germany Betahistine Sales, by Application K Tons (2022-2027)
  • Table 350. Germany Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 351. France Betahistine Sales, by Type K Tons (2022-2027)
  • Table 352. France Betahistine Sales, by Application K Tons (2022-2027)
  • Table 353. France Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 354. Italy Betahistine Sales, by Type K Tons (2022-2027)
  • Table 355. Italy Betahistine Sales, by Application K Tons (2022-2027)
  • Table 356. Italy Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 357. United Kingdom Betahistine Sales, by Type K Tons (2022-2027)
  • Table 358. United Kingdom Betahistine Sales, by Application K Tons (2022-2027)
  • Table 359. United Kingdom Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 360. Netherlands Betahistine Sales, by Type K Tons (2022-2027)
  • Table 361. Netherlands Betahistine Sales, by Application K Tons (2022-2027)
  • Table 362. Netherlands Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 363. Rest of Europe Betahistine Sales, by Type K Tons (2022-2027)
  • Table 364. Rest of Europe Betahistine Sales, by Application K Tons (2022-2027)
  • Table 365. Rest of Europe Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 366. MEA Betahistine Sales, by Country K Tons (2022-2027)
  • Table 367. MEA Betahistine Sales, by Type K Tons (2022-2027)
  • Table 368. MEA Betahistine Sales, by Application K Tons (2022-2027)
  • Table 369. MEA Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 370. Middle East Betahistine Sales, by Type K Tons (2022-2027)
  • Table 371. Middle East Betahistine Sales, by Application K Tons (2022-2027)
  • Table 372. Middle East Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 373. Africa Betahistine Sales, by Type K Tons (2022-2027)
  • Table 374. Africa Betahistine Sales, by Application K Tons (2022-2027)
  • Table 375. Africa Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 376. North America Betahistine Sales, by Country K Tons (2022-2027)
  • Table 377. North America Betahistine Sales, by Type K Tons (2022-2027)
  • Table 378. North America Betahistine Sales, by Application K Tons (2022-2027)
  • Table 379. North America Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 380. United States Betahistine Sales, by Type K Tons (2022-2027)
  • Table 381. United States Betahistine Sales, by Application K Tons (2022-2027)
  • Table 382. United States Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 383. Canada Betahistine Sales, by Type K Tons (2022-2027)
  • Table 384. Canada Betahistine Sales, by Application K Tons (2022-2027)
  • Table 385. Canada Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 386. Mexico Betahistine Sales, by Type K Tons (2022-2027)
  • Table 387. Mexico Betahistine Sales, by Application K Tons (2022-2027)
  • Table 388. Mexico Betahistine Sales, by Sales Channel K Tons (2022-2027)
  • Table 389. Betahistine: by Type(USD/Units)
  • Table 390. Research Programs/Design for This Report
  • Table 391. Key Data Information from Secondary Sources
  • Table 392. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Betahistine: by Type USD Million (2016-2021)
  • Figure 5. Global Betahistine: by Application USD Million (2016-2021)
  • Figure 6. Global Betahistine: by Sales Channel USD Million (2016-2021)
  • Figure 7. South America Betahistine Share (%), by Country
  • Figure 8. Asia Pacific Betahistine Share (%), by Country
  • Figure 9. Europe Betahistine Share (%), by Country
  • Figure 10. MEA Betahistine Share (%), by Country
  • Figure 11. North America Betahistine Share (%), by Country
  • Figure 12. Global Betahistine: by Type K Tons (2016-2021)
  • Figure 13. Global Betahistine: by Application K Tons (2016-2021)
  • Figure 14. Global Betahistine: by Sales Channel K Tons (2016-2021)
  • Figure 15. South America Betahistine Share (%), by Country
  • Figure 16. Asia Pacific Betahistine Share (%), by Country
  • Figure 17. Europe Betahistine Share (%), by Country
  • Figure 18. MEA Betahistine Share (%), by Country
  • Figure 19. North America Betahistine Share (%), by Country
  • Figure 20. Global Betahistine: by Type USD/Units (2016-2021)
  • Figure 21. Global Betahistine share by Players 2021 (%)
  • Figure 22. Global Betahistine share by Players (Top 3) 2021(%)
  • Figure 23. Global Betahistine share by Players (Top 5) 2021(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Auris Medical Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Auris Medical Holding AG (Switzerland) Revenue: by Geography 2021
  • Figure 27. TOWA PHARMACEUTICAL CO., LTD (Japan) Revenue, Net Income and Gross profit
  • Figure 28. TOWA PHARMACEUTICAL CO., LTD (Japan) Revenue: by Geography 2021
  • Figure 29. Ciclum Farma Unipessoal (Portugal) Revenue, Net Income and Gross profit
  • Figure 30. Ciclum Farma Unipessoal (Portugal) Revenue: by Geography 2021
  • Figure 31. EA Pharma Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 32. EA Pharma Co., Ltd. (Japan) Revenue: by Geography 2021
  • Figure 33. Nichi-Iko Pharmaceutical (Japan) Revenue, Net Income and Gross profit
  • Figure 34. Nichi-Iko Pharmaceutical (Japan) Revenue: by Geography 2021
  • Figure 35. DOC Generici (Italy) Revenue, Net Income and Gross profit
  • Figure 36. DOC Generici (Italy) Revenue: by Geography 2021
  • Figure 37. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 38. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2021
  • Figure 39. Orion Corporation (Finland) Revenue, Net Income and Gross profit
  • Figure 40. Orion Corporation (Finland) Revenue: by Geography 2021
  • Figure 41. HENNIG ARZNEIMITTEL GmbH & Co. KG (Germany) Revenue, Net Income and Gross profit
  • Figure 42. HENNIG ARZNEIMITTEL GmbH & Co. KG (Germany) Revenue: by Geography 2021
  • Figure 43. Disphar International B.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 44. Disphar International B.V. (Netherlands) Revenue: by Geography 2021
  • Figure 45. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 46. Mylan (United States) Revenue: by Geography 2021
  • Figure 47. Global Betahistine: by Type USD Million (2022-2027)
  • Figure 48. Global Betahistine: by Application USD Million (2022-2027)
  • Figure 49. Global Betahistine: by Sales Channel USD Million (2022-2027)
  • Figure 50. South America Betahistine Share (%), by Country
  • Figure 51. Asia Pacific Betahistine Share (%), by Country
  • Figure 52. Europe Betahistine Share (%), by Country
  • Figure 53. MEA Betahistine Share (%), by Country
  • Figure 54. North America Betahistine Share (%), by Country
  • Figure 55. Global Betahistine: by Type K Tons (2022-2027)
  • Figure 56. Global Betahistine: by Application K Tons (2022-2027)
  • Figure 57. Global Betahistine: by Sales Channel K Tons (2022-2027)
  • Figure 58. South America Betahistine Share (%), by Country
  • Figure 59. Asia Pacific Betahistine Share (%), by Country
  • Figure 60. Europe Betahistine Share (%), by Country
  • Figure 61. MEA Betahistine Share (%), by Country
  • Figure 62. North America Betahistine Share (%), by Country
  • Figure 63. Global Betahistine: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Auris Medical Holding AG (Switzerland)
  • TOWA PHARMACEUTICAL CO., LTD (Japan)
  • Ciclum Farma Unipessoal (Portugal)
  • EA Pharma Co., Ltd. (Japan)
  • Nichi-Iko Pharmaceutical (Japan)
  • DOC Generici (Italy)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Orion Corporation (Finland)
  • HENNIG ARZNEIMITTEL GmbH & Co. KG (Germany)
  • Disphar International B.V. (Netherlands)
  • Mylan (United States)
Select User Access Type

Key Highlights of Report


Feb 2021 205 Pages 56 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Betahistine Market Quantitative research analysis
Global Betahistine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Rise in Geriatric Population, Environmental Pollution, Noise Pollution " is seen as one of major growth factors of Betahistine Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
The Betahistine market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Betahistine Market Report?

Have a Query? Click Here

Other Related Reports

Pilocarpine Comprehensive Study by Type (Pilocarpine Tablets, Pilocarpine Eye Drops), Application (Dry Mouth, Gluacom or Ocular Hypertension), Distribution Channel (Hospital Pharmacies, Retail Pharma...
$ 3450
Decitabine Drug Comprehensive Study by Type (Prescription, Over-the-Counter), Application (Myelodysplastic syndrome, Acute Myeloid Leukemia), Distribution Channel (Hospital Pharmacies, Drug Store, Re...
$ 3450
Gastric Carcinomas Drugs Comprehensive Study by Drugs (Ramucirumab, Docetaxel, Doxorubicin Hydrochloride, Fluorouracil, Others), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, E-Comme...
$ 3750
Pharyngitis Tablets Comprehensive Study by Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies), Source (Viral, Bacterial), Symptoms (Sore Throat, Fever, Runny Nose, Cough, Headache...
$ 3500
Gemtuzumab Ozogamicin Drugs Comprehensive Study by Type (5mg/Vial, 4.5mg/Vial), Application (Hospital, Pharmacy) Players and Region - Global Market Outlook to 2030
$ 3500
Terbinafine Tablet Comprehensive Study by Application (Athlete's Foot, Jock Itch, Ringworm, Others), Route of Administration (Oral Medication, External Medicine), Distribution Channel (Hospital Pharm...
$ 3450